Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies

CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies. We performed a descriptive analysis of our experience in this setting. 86 patients met the criteria (From Oct/99...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2006-01, Vol.8 (1), p.50-53
Main Authors: Puente Vázquez, Javier, López-Tarruella Cobo, Sara, García-Sáenz, José A, Casado Herráez, Antonio, Moreno Antón, Fernando, Sampedro Gimeno, Teresa, Bueno Muiño, Coralia, Grande Pulido, Enrique, Martín Jiménez, Miguel, Díaz-Rubio, Eduardo
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Adenocarcinoma - radiotherapy
Adenocarcinoma - secondary
Adenocarcinoma - surgery
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
Brain Neoplasms - drug therapy
Brain Neoplasms - epidemiology
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Brain Neoplasms - surgery
Breast Neoplasms - chemistry
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Carcinoma - chemistry
Carcinoma - drug therapy
Carcinoma - epidemiology
Carcinoma - secondary
Cranial Irradiation
Disease Progression
Female
Humans
Incidence
Middle Aged
Neoplasm Proteins - analysis
Neoplasm Proteins - antagonists & inhibitors
Receptor, Epidermal Growth Factor - analysis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, ErbB-4
Retrospective Studies
Survival Analysis
Trastuzumab
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies. We performed a descriptive analysis of our experience in this setting. 86 patients met the criteria (From Oct/99 to Oct/03). CNS progression occurred in 17 patients (19.5%). Mean age of CNS progression disease patients was 45.4 years while mean age for all the patients was 50.5 years. Response rate for the entire group of patients was: OR 39.7%; CB (OR + SD) 69%. Response rate to trastuzumab based-therapy was OR 82.4% and CB 88.2 at the time of CNS progression. Median time from the start of trastuzumab therapy up to the CNS progression was 10 months. OS was 23.4 weeks. The incidence of CNS involvement is high in young metastasic breast cancer women responding to trastuzumab-based therapies. This may lead to prophylactic cranial irradiation strategies or to the early detection in asymptomatic patients to improve surgery or radiosurgery results in these patients.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-006-0095-8